Transform Your Research with CRISPR-Edited iPS Cells

The Power of CRISPR-Edited iPSCs

The convergence of induced pluripotent stem cells (iPSCs) and CRISPR gene editing is driving a transformative shift in regenerative medicine. iPSCs possess the remarkable capability to differentiate into any cell type, providing invaluable insights into disease mechanisms, drug development, and personalized therapies. When combined with CRISPR's precise gene-editing technology, the potential for advancing therapeutic applications expands significantly. This synergy between iPSCs and CRISPR is opening new avenues for creating patient-specific, genetically tailored treatments, which have the potential to revolutionize medicine.

Recent research underscores the promise of this powerful combination. A seminal study published in Nature Communications demonstrates the efficacy of CRISPR-based gene modulation in iPSC-derived cardiomyocytes, showcasing its applications in functional assays and precise gene editing (Han et al., 2023). Additionally, CRISPR-edited neurons derived from iPSCs have shown significant potential for modeling neurodegenerative diseases and exploring new treatment strategies. These advancements highlight the exciting possibilities for using iPSCs and CRISPR to drive breakthroughs in therapeutic development and personalized medicine.

EditCo’s CRISPR-Edited iPSCs

At EditCo, we’ve harnessed this powerful combination to deliver the most reliable and efficient CRISPR-edited iPSCs on the market. Whether you’re working on disease modeling, drug discovery, or gene function studies, our iPSCs offer unparalleled consistency and quality, ensuring reproducible results you can trust.

Knockout iPS Cell Lines: Achieve precise gene function and disease linkage studies with our industry-leading knockout iPSCs, designed for maximum editing efficiency without compromising cell integrity.
Knock-in iPS Cell Lines: Set the new standard for disease modeling with our knock-in iPSCs, engineered for targeted gene insertion with high accuracy.
Engineered iPS Cell Options: Choose from clones (100% guaranteed edited) or pools (high editing efficiency without single-cell sorting) to best suit your research needs.

Figure 1. Highly automated workflow for the high-throughput (HTP) screening and analysis of Knock-in efficiency at hundreds of genomic safe harbor target sites in iPSCs.^{1, 2}

Collaborations Pushing the Boundaries

We’re proud that our collaborations with leading research organizations are forging new paths in healthcare.

Collaboration with NIH on Alzheimer’s Research

In partnership with the National Institutes of Health (NIH), we are leveraging our advanced CRISPR capabilities to tackle Alzheimer’s disease. Our joint effort, the Induced Pluripotent Stem Cell Neurodegenerative Disease Initiative (iNDI), is focused on generating and screening thousands of CRISPR induced pluripotent stem cell (iPSC) clones to identify potential therapeutic targets.

Partnership with bit.bio for Cell Therapies

We are also working closely with bit.bio, a synthetic biology company, to enhance cell therapies. By combining our high-throughput CRISPR platform with bit.bio’s expertise in iPSCs, we are developing innovative solutions for complex genetic challenges. This collaboration has already resulted in a high-throughput screen of hundreds of guides across multiple genomic sites, providing invaluable data for advancing cell therapy research.

Want to learn more about these groundbreaking collaborations? Read the full article here.

Ready to take your stem cell research to the next level?

Get reliable iPSC knockouts and knock-ins with industry-leading efficiency and cell quality at EditCo. Choose from 100% edited clones or high-efficiency pools.